JNPMEDI to Showcase Global Clinical Solutions at World Conference on Lung Cancer

[Financial News] JNPMEDI, a consulting company that develops new drugs and innovative medical devices based on artificial intelligence (AI) platforms, will participate in the World Conference on Lung Cancer as it seeks to expand its presence in the global clinical-trial market.
JNPMEDI said on the 7th that it will participate in the IASLC 2026 World Conference on Lung Cancer (WCLC 2026), which will be held at COEX in Seoul from the 12th to the 15th.
The World Conference on Lung Cancer is an academic conference in the field of thoracic oncology organized by the International Association for the Study of Lung Cancer (IASLC). Researchers, medical professionals, and representatives from pharmaceutical and biotechnology companies from around the world gather to share clinical research achievements and trends in new drug development, including in lung cancer and other thoracic oncology fields.
At the conference, JNPMEDI will showcase its in-house clinical-trial solution, Maven Clinical Cloud, and its imaging solution, INTUVIO IMAGING. During the conference, it will operate an exhibition booth at COEX, demonstrate its solutions to global pharmaceutical and biotechnology companies and researchers, and provide consulting on clinical-trial operations.
Maven CDMS is a clinical-trial solution that supports electronic data capture (EDC), safety information management, and risk-based monitoring (RBM), among other functions.
INTUVIO IMAGING is an imaging clinical research organization (CRO) platform that supports the collection and quality control of clinical imaging data, as well as independent image review. It was designed to integrate clinical and imaging data management through linkage with Maven CDMS.
Through its participation in the conference, JNPMEDI plans to expand its connections with global clinical researchers and pharmaceutical and biotechnology companies and identify opportunities for cooperation in new drug development and clinical trials.
Jeong Gwon-ho, CEO of JNPMEDI, said, "WCLC 2026 is an opportunity for clinical researchers and pharmaceutical and biotechnology companies from around the world to share trends in new drug development and discuss potential cooperation. We will communicate with various partners on site and expand opportunities for cooperation that can support new drug development and clinical trials."
[email protected] Jeong Sang-hee Reporter